Manish K Aghi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3807812/publications.pdf

Version: 2024-02-01

230 papers	16,331 citations	25034 57 h-index	18130 120 g-index
238 all docs	238 docs citations	238 times ranked	27479 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex. Cancer Cell, 2012, 22, 21-35.	16.8	495
3	Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biology, 2017, 18, 234.	8.8	448
4	LONG-TERM RECURRENCE RATES OF ATYPICAL MENINGIOMAS AFTER GROSS TOTAL RESECTION WITH OR WITHOUT POSTOPERATIVE ADJUVANT RADIATION. Neurosurgery, 2009, 64, 56-60.	1.1	418
5	Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma. Cancer Research, 2012, 72, 1773-1783.	0.9	395
6	Impact of extent of resection for recurrent glioblastoma on overall survival. Journal of Neurosurgery, 2012, 117, 1032-1038.	1.6	370
7	Association of Maximal Extent of Resection of Contrast-Enhanced and Nonâ€“Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncology, 2020, 6, 495.	7.1	325
8	Human Glioblastomaâ€“Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors. Cancer Research, 2009, 69, 3472-3481.	0.9	303
9	Oncolytic viral therapies â€“ the clinical experience. Oncogene, 2005, 24, 7802-7816.	5.9	269
10	The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation. Cancer Discovery, 2019, 9, 1708-1719.	9.4	205
11	Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas. Neurosurgery, 2012, 70, 234-244.	1.1	204
12	Prodrug activation enzymes in cancer gene therapy. Journal of Gene Medicine, 2000, 2, 148-164.	2.8	191
13	Heat-shock protein peptide complexâ€“96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro-Oncology, 2014, 16, 274-279.	1.2	188
14	Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro-Oncology, 2012, 14, 942-954.	1.2	183
15	A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. Cancer Cell, 2018, 33, 874-889.e7.	16.8	180
16	Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance. Clinical Cancer Research, 2013, 19, 1773-1783.	7.0	177
17	Biology of Angiogenesis and Invasion in Glioma. Neurotherapeutics, 2009, 6, 447-457.	4.4	174
18	Tumor Cell Autophagy as an Adaptive Response Mediating Resistance to Treatments Such as Antiangiogenic Therapy. Cancer Research, 2012, 72, 4294-4299.	0.9	170

#	Article	IF	Citations
19	Tumor Stromal-Derived Factor-1 Recruits Vascular Progenitors to Mitotic Neovasculature, where Microenvironment Influences Their Differentiated Phenotypes. Cancer Research, 2006, 66, 9054-9064.	0.9	165
20	Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. Journal of Neurosurgery, 2017, 126, 191-200.	1.6	148
21	The role of surgery in the management of patients with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 503-530.	2.9	147
22	Î²1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma. Cancer Research, 2013, 73, 3145-3154.	0.9	140
23	Effect of Chemotherapy-Induced DNA Repair on Oncolytic Herpes Simplex Viral Replication. Journal of the National Cancer Institute, 2006, 98, 38-50.	6.3	135
24	New advances that enable identification of glioblastoma recurrence. Nature Reviews Clinical Oncology, 2009, 6, 648-657.	27.6	134
25	Risk factors for postoperative cerebrospinal fluid leak and meningitis after expanded endoscopic endonasal surgery. Journal of Clinical Neuroscience, 2015, 22, 48-54.	1.5	129
26	Convection-enhanced delivery for the treatment of glioblastoma. Neuro-Oncology, 2015, 17, ii3-ii8.	1.2	124
27	Rathkeâ€™s cleft cysts: review of natural history and surgical outcomes. Journal of Neuro-Oncology, 2014, 117, 197-203.	2.9	104
28	Magnetic Resonance Imaging Characteristics Predict Epidermal Growth Factor Receptor Amplification Status in Glioblastoma. Clinical Cancer Research, 2005, 11, 8600-8605.	7.0	103
29	Dissecting and rebuilding the glioblastoma microenvironment with engineered materials. Nature Reviews Materials, 2019, 4, 651-668.	48.7	103
30	Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy. Clinical Cancer Research, 2012, 18, 2930-2942.	7.0	102
31	The Role of Cancer-Associated Fibroblasts in Tumor Progression. Cancers, 2021, 13, 1399.	3.7	98
32	Impact of bevacizumab chemotherapy on craniotomy wound healing. Journal of Neurosurgery, 2011, 114, 1609-1616.	1.6	93
33	Singleâ€cell sequencing maps gene expression to mutational phylogenies in <scp>PDGF</scp> â€•and <scp>EGF</scp> â€driven gliomas. Molecular Systems Biology, 2016, 12, 889.	7.2	91
34	Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. Journal of Neuro-Oncology, 2016, 130, 543-552.	2.9	90
35	Î²1 Integrin: Critical Path to Antiangiogenic Therapy Resistance and Beyond. Cancer Research, 2014, 74, 3-7.	0.9	84
36	Tuberculum sellae meningiomas: grading scale to assess surgical outcomes using the transcranial versus transsphenoidal approach. Neurosurgical Focus, 2018, 44, E9.	2.3	81

#	Article	IF	Citations
37	Dopamine agonistâ€“resistant prolactinomas. Journal of Neurosurgery, 2011, 114, 1369-1379.	1.6	80
38	HIGD1A Regulates Oxygen Consumption, ROS Production, and AMPK Activity during Glucose Deprivation to Modulate Cell Survival and Tumor Growth. Cell Reports, 2015, 10, 891-899.	6.4	79
39	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Primary Management of Patients With Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E533-E535.	1.1	77
40	Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database. Journal of Clinical Neuroscience, 2014, 21, 1490-1496.	1.5	76
41	Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro-Oncology. Journal of Neuro-Oncology, 2020, 147, 525-529.	2.9	76
42	Factors predicting postoperative hyponatremia and efficacy of hyponatremia management strategies after more than 1000 pituitary operations. Journal of Neurosurgery, 2013, 119, 1478-1483.	1.6	75
43	Improved versus worsened endocrine function after transsphenoidal surgery for nonfunctional pituitary adenomas: rate, time course, and radiological analysis. Journal of Neurosurgery, 2016, 124, 589-595.	1.6	75
44	Contribution of Bone Marrow-Derived Cells to Blood Vessels in Ischemic Tissues and Tumors. Molecular Therapy, 2005, 12, 994-1005.	8.2	74
45	MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro-Oncology, 2010, 12, 822-833.	1.2	74
46	Bone involvement predicts poor outcome in atypical meningioma. Journal of Neurosurgery, 2009, 111, 464-471.	1.6	73
47	A Comprehensive Long-term Retrospective Analysis of Silent Corticotrophic Adenomas vs Hormone-Negative Adenomas. Neurosurgery, 2013, 73, 8-18.	1.1	73
48	Factors Predicting Recurrence After Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities. Neurosurgery, 2015, 76, 179-186.	1.1	72
49	Sinonasal morbidity following endoscopic endonasal skull base surgery. Clinical Neurology and Neurosurgery, 2015, 130, 162-167.	1.4	71
50	Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. Journal of Neuro-Oncology, 2009, 92, 401-415.	2.9	68
51	Endoscopic surgery for tuberculum sellae meningiomas: a systematic review and meta-analysis. Neurosurgical Review, 2013, 36, 349-359.	2.4	68
52	Nationwide shift from microscopic to endoscopic transsphenoidal pituitary surgery. Pituitary, 2016, 19, 248-250.	2.9	68
53	Fibronectin in malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications. Seminars in Oncology, 2019, 46, 284-290.	2.2	68
54	Suprasellar Rathke Cleft Cysts. Neurosurgery, 2011, 69, 1058-1069.	1.1	65

#	Article	IF	Citations
55	Hypoxia Enhances the Replication of Oncolytic Herpes Simplex Virus. Molecular Therapy, 2009, 17, 51-56.	8.2	64
56	Angiogenic Response Caused by Oncolytic Herpes Simplex Virusâ€“Induced Reduced Thrombospondin Expression Can Be Prevented by Specific Viral Mutations or by Administering a Thrombospondin-Derived Peptide. Cancer Research, 2007, 67, 440-444.	0.9	62
57	Neurosurgical Management and Prognosis of Patients With Glioblastoma That Progresses During Bevacizumab Treatment. Neurosurgery, 2012, 70, 361-370.	1.1	60
58	Hypophysitis: a single-center case series. Pituitary, 2015, 18, 630-641.	2.9	60
59	Pituicytomas and spindle cell oncocytomas: modern case series from the University of California, San Francisco. Pituitary, 2015, 18, 150-158.	2.9	60
60	Cross-activating c-Met/Î²1 integrin complex drives metastasis and invasive resistance in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8685-E8694.	7.1	60
61	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for the Management of Patients With Residual or Recurrent Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E539-E540.	1.1	59
62	Hypoxia-induced tumor cell autophagy mediates resistance to anti-angiogenic therapy. Autophagy, 2012, 8, 979-981.	9.1	57
63	The genetic landscape of gliomas arising after therapeutic radiation. Acta Neuropathologica, 2019, 137, 139-150.	7.7	57
64	Morbidity of repeat transsphenoidal surgery assessed in more than 1000 operations. Journal of Neurosurgery, 2014, 121, 67-74.	1.6	56
65	Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. Nature Communications, 2020, 11, 4803.	12.8	56
66	Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy. Journal of Neurosurgery, 2018, 130, 1-8.	1.6	54
67	The prognostic implications of Hyamâ€™s subtype for patients with Kadish stage C esthesioneuroblastoma. Journal of Clinical Neuroscience, 2013, 20, 281-286.	1.5	51
68	Convection-enhanced drug delivery for glioblastoma: a review. Journal of Neuro-Oncology, 2021, 151, 415-427.	2.9	50
69	GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. JCI Insight, 2017, 2, e88815.	5.0	49
70	Breast Adenocarcinoma Metastatic to Epidural Cervical Spine Meningioma: Case Report and Review of the Literature. Journal of Neuro-Oncology, 2005, 75, 149-155.	2.9	48
71	Endoscopic skull base and transoral surgery during <scp>COVID</scp>â€19 pandemic: Minimizing droplet spread with <scp>negativeâ€pressure</scp> otolaryngology viral isolation drape. Head and Neck, 2020, 42, 1577-1582.	2.0	47
72	Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. Neuro-Oncology Advances, 2021, 3, vdab100.	0.7	47

#	Article	IF	Citations
73	Excess mortality for patients with residual disease following resection of pituitary adenomas. Pituitary, 2011, 14, 276-283.	2.9	46
74	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Surgical Techniques and Technologies for the Management of Patients With Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E536-E538.	1.1	44
75	Safety and outcomes of resection of butterfly glioblastoma. Neurosurgical Focus, 2018, 44, E4.	2.3	43
76	The Path to U.S. Neurosurgical Residency for Foreign Medical Graduates: Trends from a Decade 2007â€“2017. World Neurosurgery, 2020, 137, e584-e596.	1.3	42
77	Phase Ib Trial of Oncolytic Herpes Virus G207 Shows Safety of Multiple Injections and Documents Viral Replication. Molecular Therapy, 2009, 17, 8-9.	8.2	41
78	Systemic therapy for brain metastases. Critical Reviews in Oncology/Hematology, 2019, 142, 44-50.	4.4	41
79	Meningioma metastases: incidence and proposed screening paradigm. Journal of Neurosurgery, 2020, 132, 1447-1455.	1.6	41
80	Management of recurrent and refractory Cushing disease. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 560-568.	2.8	40
81	A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. Journal of Neurosurgery, 2011, 115, 754-759.	1.6	40
82	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pretreatment Endocrine Evaluation of Patients With Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E527-E529.	1.1	40
83	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Patients With Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, 521-523.	1.1	38
84	Tumor treating fields: a new approach to glioblastoma therapy. Journal of Neuro-Oncology, 2018, 137, 447-453.	2.9	38
85	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neuro-Oncology, 2020, 22, 1568-1579.	1.2	38
86	Viral Therapy for Glioblastoma. Cancer Journal (Sudbury, Mass), 2003, 9, 167-179.	2.0	36
87	Neuropilin-1 modulates TGFÎ² signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy. PLoS ONE, 2017, 12, e0185065.	2.5	35
88	Disparities in health care determine prognosis in newly diagnosed glioblastoma. Neurosurgical Focus, 2018, 44, E16.	2.3	35
89	Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. Acta Neuropathologica Communications, 2020, 8, 151.	5.2	35
90	Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neuro-Oncology Advances, 2020, 2, vdaa142.	0.7	35

#	Article	IF	Citations
91	Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance. Cancer Research, 2020, 80, 1498-1511.	0.9	35
92	Heparin-induced Thrombocytopenia Type II in Subarachnoid Hemorrhage Patients: Incidence and Complications. Neurosurgery, 2005, 57, 243-248.	1.1	34
93	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Posttreatment Follow-up Evaluation of Patients With Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E541-E543.	1.1	34
94	Factors associated with delay to pituitary adenoma diagnosis in patients with visual loss. Journal of Neurosurgery, 2012, 116, 283-289.	1.6	33
95	Resection and brain brachytherapy with permanent iodine-125 sources for brain metastasis. Journal of Neurosurgery, 2016, 126, 1749-1755.	1.6	33
96	Indications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience. Neurosurgery, 2017, 80, 129-139.	1.1	33
97	Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro-Oncology, 2018, 20, 632-641.	1.2	33
98	WHO Grade I Meningioma Recurrence: Identifying High Risk Patients Using Histopathological Features and the MIB-1 Index. Frontiers in Oncology, 2020, 10, 1522.	2.8	33
99	Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes. Oncotarget, 2019, 10, 2212-2223.	1.8	33
100	Nuclear Localization of the Mitochondrial Factor HIGD1A during Metabolic Stress. PLoS ONE, 2013, 8, e62758.	2.5	32
101	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Pretreatment Ophthalmology Evaluation in Patients With Suspected Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E530-E532.	1.1	32
102	Cavernous and inferior petrosal sinus sampling and dynamic magnetic resonance imaging in the preoperative evaluation of Cushingâ€™s disease. Journal of Neuro-Oncology, 2014, 116, 593-600.	2.9	31
103	Metabolic Drivers of Invasion in Glioblastoma. Frontiers in Cell and Developmental Biology, 2021, 9, 683276.	3.7	31
104	INCREASED PREVALENCE OF OBESITY AND OBESITY-RELATED POSTOPERATIVE COMPLICATIONS IN MALE PATIENTS WITH MENINGIOMAS. Neurosurgery, 2007, 61, 754-761.	1.1	30
105	Improved Survival with Decreased Wait Time to Surgery in Glioblastoma Patients Presenting with Seizure. Neurosurgery, 2017, 81, 824-833.	1.1	30
106	Management of recurrent and refractory Cushing's disease with reoperation and/or proton beam radiosurgery. Clinical Neurosurgery, 2008, 55, 141-4.	0.2	30
107	Surgical outcomes in choroid plexus papillomas: an institutional experience. Journal of Neuro-Oncology, 2013, 113, 117-125.	2.9	29
108	Postoperative Delirium in Glioblastoma Patients: Risk Factors and Prognostic Implications. Neurosurgery, 2018, 83, 1161-1172.	1.1	29

#	Article	IF	Citations
109	Detection of glioma infiltration at the tumor margin using quantitative stimulated Raman scattering histology. Scientific Reports, 2021, 11, 12162.	3.3	28
110	Incidence of headache as a presenting complaint in over 1000 patients with sellar lesions and factors predicting postoperative improvement. Clinical Neurology and Neurosurgery, 2015, 132, 16-20.	1.4	27
111	Ventriculoperitoneal Shunting for Glioblastoma: Risk Factors, Indications, and Efficacy. Neurosurgery, 2017, 80, 421-430.	1.1	27
112	Infected Rathke Cleft Cysts. Neurosurgery, 2010, 67, 762-769.	1.1	26
113	Autophagy as a mechanism for anti-angiogenic therapy resistance. Seminars in Cancer Biology, 2020, 66, 75-88.	9.6	26
114	Salvage therapy outcomes for atypical meningioma. Journal of Neuro-Oncology, 2018, 138, 425-433.	2.9	25
115	ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma. Genome Biology, 2021, 22, 311.	8.8	25
116	Cost-Effectiveness Analysis of Surgical versus Medical Treatment of Prolactinomas. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, 125-131.	0.8	24
117	Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. Clinical Cancer Research, 2021, 27, 3916-3925.	7.0	24
118	Use of thrombin-based hemostatic matrix during meningioma resection: A potential risk factor for perioperative thromboembolic events. Clinical Neurology and Neurosurgery, 2014, 119, 116-120.	1.4	22
119	Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin Î²1 Blocking Antibody OS2966. Molecular Cancer Therapeutics, 2019, 18, 1127-1136.	4.1	22
120	Developing an Algorithm for Optimizing Care of Elderly Patients With Glioblastoma. Neurosurgery, 2018, 82, 64-75.	1.1	22
121	Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution. Neurosurgical Focus, 2020, 48, E13.	2.3	22
122	Socioeconomic factors associated with pituitary apoplexy. Journal of Neurosurgery, 2013, 119, 1432-1436.	1.6	21
123	Outcomes and patterns of care in adult skull base chondrosarcomas from the SEER database. Journal of Clinical Neuroscience, 2014, 21, 1497-1502.	1.5	21
124	Interventional MRI-guided catheter placement and real time drug delivery to the central nervous system. Expert Review of Neurotherapeutics, 2016, 16, 635-639.	2.8	21
125	Functional brain mapping: overview of techniques and their application to neurosurgery. Neurosurgical Review, 2019, 42, 639-647.	2.4	21
126	Surgical Cavity Constriction and Local Progression Between Resection and Adjuvant Radiosurgery for Brain Metastases. Cureus, 2016, 8, e575.	0.5	21

#	Article	IF	Citations
127	Rate and Time Course of Improvement in Endocrine Function After More Than 1000 Pituitary Operations. Neurosurgery, 2014, 61, 163-166.	1.1	20
128	Surgical resection of fourth ventricular ependymomas: case series and technical nuances. Journal of Neuro-Oncology, 2016, 130, 341-349.	2.9	20
129	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Preoperative Imaging Assessment of Patients With Suspected Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E524-E526.	1.1	20
130	Management of Chordoma and Chondrosarcoma with Fractionated Stereotactic Radiotherapy. Frontiers in Surgery, 2017, 4, 35.	1.4	20
131	Atypical pituitary adenoma: a clinicopathologic case series. Journal of Neurosurgery, 2018, 128, 1058-1065.	1.6	20
132	The immunology of low-grade gliomas. Neurosurgical Focus, 2022, 52, E2.	2.3	20
133	Unilateral vestibular schwannoma with other neurofibromatosis Type 2â€“related tumors: clinical and molecular study of a unique phenotype. Journal of Neurosurgery, 2006, 104, 201-207.	1.6	19
134	Disseminated progression of glioblastoma after treatment with bevacizumab. Clinical Neurology and Neurosurgery, 2013, 115, 1795-1801.	1.4	19
135	Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. World Neurosurgery, 2019, 124, 397-409.	1.3	19
136	Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes. Journal of Neurosurgery, 2019, 131, 147-153.	1.6	19
137	Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma. Scientific Reports, 2020, 10, 17580.	3.3	19
138	Preventing Delays in First-Case Starts on the Neurosurgery Service: A Resident-Led Initiative at an Academic Institution. Journal of Surgical Education, 2016, 73, 291-295.	2.5	18
139	Incorporating Tumor-Associated Macrophages into Engineered Models of Glioma. IScience, 2020, 23, 101770.	4.1	18
140	Mechanisms of evasion to antiangiogenic therapy in glioblastoma. Clinical Neurosurgery, 2010, 57, 123-8.	0.2	18
141	Biomarkers predicting tumor response and evasion to anti-angiogenic therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 86-100.	7.4	17
142	Petrous Face Meningiomas: Classification, Clinical Syndromes, and Surgical Outcomes. World Neurosurgery, 2018, 114, e1266-e1274.	1.3	17
143	Hyperostosing sphenoid wing meningiomas: surgical outcomes and strategy for bone resection and multidisciplinary orbital reconstruction. Journal of Neurosurgery, 2021, 134, 711-720.	1.6	17
144	Viral vectors as therapeutic agents for glioblastoma. Current Opinion in Molecular Therapeutics, 2005, 7, 419-30.	2.8	17

#	Article	IF	Citations
145	Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. Neurosurgery, 2022, 90, 124-130.	1.1	17
146	Role of a p53 polymorphism in the development of nonfunctional pituitary adenomas. Molecular and Cellular Endocrinology, 2017, 446, 81-90.	3.2	16
147	A cross-sectional study of neurosurgical department chairs in the United States. Journal of Neurosurgery, 2018, 129, 1342-1348.	1.6	16
148	Surgical Outcomes, Complications, and Management Strategies for Foramen Magnum Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, 001-009.	0.8	16
149	Gangliogliomas of the optic pathway. Journal of Clinical Neuroscience, 2014, 21, 2244-2249.	1.5	15
150	Extended endoscopic endonasal approach for suprasellar Rathkeâ€™s cleft cysts. Journal of Clinical Neuroscience, 2014, 21, 779-785.	1.5	15
151	The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment. Journal of Neuro-Oncology, 2020, 148, 131-139.	2.9	15
152	Genetically Engineered Herpes Simplex Viral Vectors in the Treatment of Brain Tumors: A Review. Cancer Investigation, 2003, 21, 278-292.	1.3	14
153	The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma. Academic Radiology, 2016, 23, 1073-1082.	2.5	14
154	Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions. Seminars in Cancer Biology, 2022, 86, 532-541.	9.6	14
155	Interfacility neurosurgical transfers: an analysis of nontraumatic inpatient and emergency department transfers with implications for improvements in care. Journal of Neurosurgery, 2019, 131, 281-289.	1.6	13
156	Molecular Biology of Pituitary Adenomas. Neurosurgery Clinics of North America, 2019, 30, 391-400.	1.7	13
157	Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma. Frontiers in Oncology, 2021, 11, 812916.	2.8	13
158	Gene therapy for glioblastoma. Neurosurgical Focus, 2006, 20, E18.	2.3	13
159	Immunotherapy Resistance in Glioblastoma. Frontiers in Genetics, 2021, 12, 750675.	2.3	13
160	Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q. Journal of Neuro-Oncology, 2009, 93, 115-20.	2.9	12
161	Optimizing glioblastoma resection: intraoperative mapping and beyond. CNS Oncology, 2014, 3, 359-366.	3.0	12
162	Role of c-Met/Î²1 integrin complex in the metastatic cascade in breast cancer. JCI Insight, 2021, 6, .	5.0	12

#	Article	IF	Citations
163	Intracranial subdural osteoma: A rare benign tumor that can be differentiated from other calcified intracranial lesions utilizing MR imaging. Journal of Neuroradiology, 2012, 39, 263-266.	1.1	11
164	Anti-angiogenic therapies in the management of glioblastoma. Chinese Clinical Oncology, 2021, 10, 37-37.	1.2	11
165	Identifying risk factors for postoperative diabetes insipidus in more than 2500 patients undergoing transsphenoidal surgery: a single-institution experience. Journal of Neurosurgery, 2022, 137, 647-657.	1.6	11
166	Tumors of the anterior skull base. Expert Review of Neurotherapeutics, 2014, 14, 425-438.	2.8	10
167	Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome. Neurosurgery, 2019, 85, 793-800.	1.1	10
168	Atypical meningiomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 170, 233-244.	1.8	10
169	Prospective genomically guided identification of â€œearly/evolvingâ€•and â€œundersampledâ€•IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro-Oncology, 2022, 24, 1749-1762.	1.2	10
170	Impact of platybasia and anatomic variance on surgical approaches to the craniovertebral junction. Laryngoscope, 2014, 124, 1760-1766.	2.0	9
171	A Safe Transitions Pathway for post-craniotomy neurological surgery patients: high-value care that bypasses the intensive care unit. Journal of Neurosurgery, 2021, 134, 1386-1391.	1.6	9
172	A predictive algorithm for evaluating elevated serum prolactin in patients with a sellar mass. Journal of Clinical Neuroscience, 2015, 22, 155-160.	1.5	8
173	Approach to the postoperative patient with Cushingâ€™s disease. Pituitary, 2015, 18, 232-237.	2.9	8
174	Medical versus surgical treatment of prolactinomas: an analysis of treatment outcomes. Expert Review of Endocrinology and Metabolism, 2018, 13, 25-33.	2.4	8
175	CD97 is associated with mitogenic pathway activation, metabolic reprogramming, and immune microenvironment changes in glioblastoma. Scientific Reports, 2022, 12, 1464.	3.3	8
176	Epidermal growth factor-like module containing mucin-like hormone receptor 2 expression in gliomas. Journal of Neuro-Oncology, 2015, 121, 53-61.	2.9	7
177	Patients cured of acromegaly do not experience improvement of their skull deformities. Pituitary, 2017, 20, 292-294.	2.9	7
178	Comparative Analysis of Survival Outcomes and Prognostic Factors of Supratentorial versus Cerebellar Glioblastoma in the Elderly: Does Location Really Matter?. World Neurosurgery, 2021, 146, e755-e767.	1.3	7
179	Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies. Journal of Neuro-Oncology, 2021, 152, 1-13.	2.9	7
180	Recent advances in the treatment of acromegaly. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 304-307.	2.3	6

#	Article	IF	Citations
181	Microarray Analysis in Glioblastomas. Methods in Molecular Biology, 2015, 1375, 195-206.	0.9	6
182	Shunt Treatment for Coccidioidomycosis-Related Hydrocephalus: A Single-Center Series. World Neurosurgery, 2020, 138, e883-e891.	1.3	6
183	Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair. Clinical Neurosurgery, 2006, 53, 65-76.	0.2	6
184	Strategies to Address Projected Challenges Facing Foreign Applicants in the U.S. Neurosurgery Match. World Neurosurgery, 2020, 138, 553-555.	1.3	5
185	Sarcopenia Diagnosed Using Masseter Muscle Diameter as a Survival Correlate in Elderly Patients with Glioblastoma. World Neurosurgery, 2022, 161, e448-e463.	1.3	5
186	Determinants of initial bone graft volume loss in posterolateral lumbar fusion. Journal of Clinical Neuroscience, 2011, 18, 1193-1196.	1.5	4
187	Getting More Out of Radiation Therapy in Glioblastoma. Neuro-Oncology, 2014, 16, 4-6.	1.2	4
188	Adaptation to antiangiogenic therapy in neurological tumors. Cellular and Molecular Life Sciences, 2015, 72, 3069-3082.	5.4	4
189	Letter to the Editor Regarding â€œGeographic Distribution of International Medical Graduate Residents in U.S. Neurosurgery Training Programsâ€. World Neurosurgery, 2020, 138, 591.	1.3	4
190	Plurihormonal PIT-1â€“Positive Pituitary Adenomas: A Systematic Review and Single-Center Series. World Neurosurgery, 2021, 151, e185-e191.	1.3	4
191	Geographic landscape of foreign medical graduates in US neurosurgery training programs from 2007 to 2017. Clinical Neurology and Neurosurgery, 2021, 209, 106891.	1.4	4
192	Intraoperative Conversion from Endoscopic to Open Transcortical Transventricular Removal of Colloid Cysts as a Salvage Procedure. Cureus, 2015, 7, e247.	0.5	4
193	Socioeconomic predictors of case presentations and outcomes in 225 nonfunctional pituitary adenoma resections. Journal of Neurosurgery, 2022, 136, 1325-1336.	1.6	4
194	Cerebrospinal Fluid Leaks and Pseudomeningocele after Posterior Fossa Surgery: Effect of an Autospray Dural Sealant. Cureus, 2020, 12, e8379.	0.5	4
195	Increased prevalence of obesity and obesity-related postoperative complications in male meningioma patients. Clinical Neurosurgery, 2007, 54, 236-40.	0.2	4
196	The Role of Single-Nucleotide Polymorphisms in Pituitary Adenomas Tumorigenesis. Cancers, 2019, 11, 1977.	3.7	3
197	Recent advancements in the molecular biology of pituitary adenomas. Expert Review of Endocrinology and Metabolism, 2022, 17, 293-304.	2.4	3
198	The Endoscopic Buccal Fat Pad Flap for Closure of Skull Base Defects: A Report of 5 Cases. World Neurosurgery, 2018, 110, e42-e45.	1.3	2

#	Article	IF	Citations
199	Beyond guidelines: analysis of current practice patterns of AANS/CNS tumor neurosurgeons. Journal of Neuro-Oncology, 2021, 151, 361-366.	2.9	2
200	Meningioma surgical outcomes and complications in patients aged 75Âyears and older. Journal of Clinical Neuroscience, 2021, 88, 88-94.	1.5	2
201	Effect of facility volume on giant pituitary adenoma neurosurgical outcomes. Journal of Neurosurgery, 2022, , 1-10.	1.6	2
202	Surgery for Control of Brain Metastases After Previous Checkpoint Inhibitor Immunotherapy. World Neurosurgery, 2022, 162, e235-e245.	1.3	2
203	Interval, acute onset airway obstruction associated with a fracture of the C4 vertebra in a patient with ankylosing spondylitis. Journal of Clinical Neuroscience, 2010, 17, 1085-1088.	1.5	1
204	Headache and Focal Neurologic Deficits in a 37-Year-Old Woman. JAMA Neurology, 2013, 70, 1445.	9.0	1
205	Introduction to Pituitary Adenomas. Neurosurgery Clinics of North America, 2019, 30, xiii.	1.7	1
206	Introduction to special issue dedicated to the 35th anniversary of the joint section on tumors. Journal of Neuro-Oncology, 2021, 151, 341-343.	2.9	1
207	Trends in physician reimbursements and procedural volumes for radiosurgery versus open surgery in brain tumor care: an analysis of Medicare data from 2009 to 2018. Journal of Neurosurgery, 2022, 136, 97-108.	1.6	1
208	The Evolving Role of Neurosurgical Intervention for Central Nervous System Tumors. Hematology/Oncology Clinics of North America, 2022, 36, 63-75.	2.2	1
209	Antiangiogenic Therapy for Glioblastoma. , 2016, , 143-149.		1
210	Correction: Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes. Oncotarget, 2019, 10, 4350-4350.	1.8	1
211	Preface. Neurosurgery Clinics of North America, 2012, 23, ix.	1.7	0
212	Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14024.	4.1	0
213	BMET-24CRANIOTOMY FOR TUMOR RESECTION IN PATIENTS WITH MULTIPLE BRAIN METASTASES: CHARACTERISTIC OF THE DOMINANT METASTATIC LESION. Neuro-Oncology, 2015, 17, v50.2-v50.	1.2	0
214	ACTR-33. AÂPHASE IÂSTUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA. Neuro-Oncology, 2016, 18, vi9-vi9.	1.2	0
215	TMOD-24. AÂNOVEL XENOGRAFT MODEL REVEALS AÂGENE CASCADE DEFINING AÂMESENCHYMAL TRANSITION DURING THE EVOLUTION OF RESISTANCE TO ANTI-ANGIOGENIC THERAPY. Neuro-Oncology, 2016, 18, vi212-vi212.	1.2	0
216	Initial Experience with Intraoperative Phosphorous-32 Brachytherapy During Resection of Malignant Spinal Tumors. World Neurosurgery, 2018, 115, e785-e793.	1.3	0

#	Article	IF	Citations
217	Endoscope Image Capture System with Mirrorless Camera. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, 079-081.	0.8	0
218	Letter to the Editor Regarding â€œGlobal Diversity and Academic Success of Foreign-Trained Academic Neurosurgeons in the United Statesâ€. World Neurosurgery, 2020, 139, 704-705.	1.3	0
219	In Reply to the Letter to the Editor â€œRegarding the Path to U.S. Neurosurgical Residency for Foreign Medical Graduates: Trends from a Decade 2007â€“2017â€. World Neurosurgery, 2020, 143, 625.	1.3	0
220	In Reply to the Letter to the Editor Regarding â€œThe Path to U.S. Neurosurgical Residency for Foreign Medical Graduates: Trends from a Decade 2007â€“2017â€. World Neurosurgery, 2020, 138, 594.	1.3	0
221	Can Private versus Government Insurance Predict Neurosurgical Outcomes? An Analysis of 218 Nonfunctional Pituitary Adenoma Resections across Seven Years. , 2021, 82, .		0
222	Does Having a Primary Care Physician Predict Neurosurgical Outcomes? An Analysis of 225 Nonfunctional Pituitary Adenoma Resections across Seven Years. , 2021, 82, .		0
223	OTME-12. Role of the transsulfuration pathway in glioblastoma invasion. Neuro-Oncology Advances, 2021, 3, ii15-ii16.	0.7	0
224	Presentation and management of post-operative cerebrospinal fluid leaks after sphenoclival expanded endonasal surgery: A single institution experience. Journal of Clinical Neuroscience, 2021, 91, 13-19.	1.5	0
225	Pituitary Apoplexy. , 2017, , 499-516.		0
226	Atypical Pituitary Adenoma: A Clinicopathologic Case Series. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.8	0
227	Neuroendocrinological Outcomes Following Early versus Delayed Surgery for Acute Pituitary Apoplexy. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.8	0
228	Economic Burden and Cost-effectiveness of Endoscopic versus Microscopic Transsphenoidal Surgery for Pituitary Adenomas. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, .	0.8	0
229	Salvage surgery for local control of brain metastases after prior stereotactic radiosurgery: a single-center series. World Neurosurgery, 2021, , .	1.3	0
230	Lateral orientation of Rathke cleft cysts may be associated with high rates of recurrence after surgery. Pituitary, 0, , .	2.9	0